Cellectis gives Bayer access to homologous recombination patents

Cellectis, a French genome engineering company, and Bayer Healthcare have signed an agreement under which Bayer will have access to Cellectis" WO9011354 patent family covering homologous recombination aimed at introducing new features into the genome.

Cellectis, a French genome engineering company, and Bayer Healthcare have signed an agreement under which Bayer will have access to Cellectis" WO9011354 patent family covering homologous recombination aimed at introducing new features into the genome.

This global licence includes the use of the Institut Pasteur technology relating to homologous recombination to obtain and use certain transgenic animals in pharmaceutical research, in all countries, including Japan. Financial terms were not disclosed.

"Our licensing strategy is central to our business model and allows us to receive fair payment for the scientific and industrial advancements made possible by this technology. It continues to have a strong influence on the evolution of the company, as demonstrated by Cellectis" progress in the last ten years, and is an important component of our future growth strategy," said Cellectis" ceo Andre Choulika.

Companies